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Abstract
We and others have previously isolated inﬂuenza B viruses with reduced sensitivity to neuraminidase (NA) inhibitors (oseltamivir and
zanamivir) from patients who were never exposed to these drugs. It was unclear whether the NA substitutions found in these inﬂu-
enza B isolates arose spontaneously or were caused by selective pressure. Here, we obtained inﬂuenza B viruses with reduced NA
inhibitor sensitivity by in vitro selection with NA inhibitors. We found that these viruses possessed the same NA substitutions as those
previously found in viruses isolated from untreated patients. These results suggest that these NA substitutions were selected in patients
who were treated with an NA inhibitor and that the resistant variants were then transmitted to others.
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Although neuraminidase (NA) inhibitors, oseltamivir and za-
namivir, are globally used to treat inﬂuenza, they will become
obsolete once inﬂuenza viruses develop resistance to them.
For inﬂuenza B viruses isolated from patients treated with
NA inhibitors, several amino acid substitutions in NA have
been identiﬁed that confer NA inhibitor resistance: arginine-
to-lysine, aspartic acid-to-asparagine/tyrosine and glycine-to-
serine substitutions at positions 152 (Arg152 ﬁ Lys), 198
(Asp198 ﬁ Asn/Tyr), and 402 (Gly402 ﬁ Ser), respectively
[1–4]. However, several inﬂuenza B viruses with reduced
NA inhibitor sensitivity have been isolated from patients
who were not treated with NA inhibitors. These viruses
possess the following amino acid substitutions in NA that
were not found in concurrently circulating viruses: aspartic
acid-to-asparagine/glutamine, isoleucine-to-threonine, serine-
to-glycine, histidine-to-tyrosine and arginine-to-lysine at
positions 198 (Asp198 ﬁ Asn/Glu), 222 (Ile222 ﬁ Thr),
250 (Ser250 ﬁ Gly), 274 (His274 ﬁ Tyr) and 371
(Arg371 ﬁ Lys), rspectively [3,5,6]. The sensitivity of some
of these viruses to NA inhibitors was not dramatically
reduced as compared with that of isolates from NA inhibitor-
treated patients. For example, NA Ile222 ﬁ Thr-possessing
isolates from patients who were not drug-treated exhibited
only six-fold to seven-fold and two-fold to three-fold reduced
sensitivity to oseltamivir and zanamivir, respectively, as com-
pared with the median 50% inhibitory concentration (IC50)
values for type B viruses [3], whereas the zanamivir sen-
sitivity of an NA Arg152 ﬁ Lys-possessing virus that was
isolated from an immunocompromised inﬂuenza patient
treated with zanamivir was 1000-fold lower than that of the
pretreated isolate [2]. Therefore, it was unclear whether the
NA substitutions found in the inﬂuenza B isolates from
patients who were not treated with the drugs arose sponta-
neously. Interestingly, there have been no reports of in vitro
selection of inﬂuenza B viruses resistant to oseltamivir, which
is the most extensively used NA inhibitor in clinical practice.
In fact, only a glutamine-to-glycine/aspartic acid substitution
at position 119 (Glu119 ﬁ Gly/Asp) and a His274 ﬁ Tyr
substitution were detected in the NA of viruses passaged in
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cell culture experiments with zanamivir or peramivir [7–11].
To determine whether the NA substitutions found in the
inﬂuenza B isolates from patients who were not treated with
the drugs arose because of selective pressure by the drugs,
we attempted to select NA inhibitor-resistant viruses in vitro.
We serially passaged B/Yokohama/UT2119/2005 virus in
Madin-Darby canine kidney (MDCK) cells and MDCK cells
expressing the human b-galactoside a2,6-sialyltransferase I
gene (MDCK-ST6 cells) [12] with a 1 lM concentration
of either oseltamivir carboxylate (Roche Products, Basel,
Switzerland), which is the active metabolite of oseltamivir, or
zanamivir (GlaxoSmithKline, Brentford, UK). Conﬂuent
monolayers of these cells were infected with ten-fold dilu-
tions of virus (10)3 to 10)8), and the supernatants of the
cytopathic effect-positive wells that were infected with the
second-highest dilution of virus were subjected to subse-
quent passages. After 20 passages, IC50 values of viruses for
oseltamivir and zanamivir were determined by using a ﬂuo-
rescence-based sialidase inhibition assay [3,12]. In this way,
we could select viruses with reduced sensitivity to NA inhib-
itors (see below for details): passage no (P)20-CK-ZV was
passaged in MDCK cells with zanamivir, and P20-ST6-OV
was passaged in MDCK-ST6 cells with oseltamivir (data not
shown).
In addition to NA, haemagglutinin (HA) is also known to
affect the sensitivity of viruses to NA inhibitors [13,14].
Therefore, to identify the amino acid substitution(s) respon-
sible for conferring NA inhibitor resistance, we cloned the
NA and HA genes of P20-CK-ZV into a cloning vector as
described previously [3]. Sequence analysis of at least ﬁve
cDNA clones of each gene revealed that two-thirds (six of
nine clones) of P20-CK-ZV possessed NA Asp198 ﬁ Asn
and all had HA2 Arg65 ﬁ Gly (seven of seven clones) sub-
stitutions (Table 1). By retrospective analyses, we found
that the NA Asp198 ﬁ Asn and HA2 Arg65 ﬁ Gly substi-
tutions emerged at passages 12 and 18, respectively. Simi-
larly, we sequenced the NA and HA genes of P20-ST6-OV,
and found NA Ile222 ﬁ Thr (ﬁve of eight clones) and HA1
Ile307 ﬁ Thr (ﬁve of seven clones) substitutions (Table 1):
the NA Ile222 ﬁ Thr and HA1 Ile307 ﬁ Thr substitutions
were ﬁrst detected at passages 18 and 17, respectively.
When B/Yokohama/UT2119/2005 virus was passaged 20
times without drugs, we detected only a lysine-to-arginine
substitution at position 382 in HA, which is structurally far
from the receptor-binding site and, therefore unlikely to
affect receptor binding or NA inhibitor susceptibility.
We then plaque-puriﬁed P15-CK-ZV, P20-CK-ZV and
P20-ST6-OV, and obtained three cloned viruses: PP-P15-CK-
ZV with the NA Asp198 ﬁ Asn substitution, PP-P20-CK-ZV
with the NA Asp198 ﬁ Asn and HA2 Arg65 ﬁ Gly substi-
tutions, and PP-P20-ST6-OV with the NA Ile222 ﬁ Thr and
HA1 Ile307 ﬁ Thr substitutions (Table 2). Despite the
extensive plaque puriﬁcation of P20-ST6-OV, we could not
obtain viruses possessing only the NA Ile222 ﬁ Thr substi-
tution. These puriﬁed viruses were subjected to a sialidase
inhibition assay to determine the IC50 values for oseltamivir
and zanamivir (Table 2). As compared with the parent virus,
the NA Asp198 ﬁ Asn substitution conferred 3.0–3.2-fold
and 4.9–5.8-fold higher resistance against oseltamivir and
zanamivir, respectively, and the NA Ile222 ﬁ Thr substitu-
tion conferred 7.2-fold and 2.1-fold higher resistance against
oseltamivir and zanamivir, respectively.
We have reported that several inﬂuenza B viruses with
reduced sensitivity to oseltamivir and/or zanamivir were iso-
lated from untreated patients in Japan, where these drugs
are extensively used [3]. The IC50 values of the clinical iso-
TABLE 1. Properties of inﬂuenza B viruses after passage in the presence of neuraminidase (NA) inhibitors
Virus passage condition Virus
Number of molecular clones possessing amino acid substitutiona in:
NA HA2 HA1
Asp198 ﬁ Asn Ile222 ﬁ Thr Arg65 ﬁ Gly Ile307 ﬁ Thr
In MDCK cells with zanamivir P10b-CK-ZV 0/5 clones ND 0/6 clones ND
P12-CK-ZV 1/8 clones ND NT ND
P14-CK-ZV 2/7 clones ND NT ND
P15-CK-ZV 7/7 clones ND 0/7 clones ND
P16-CK-ZV 4/5 clones ND 0/5 clones ND
P18-CK-ZV 5/6 clones ND 3/8 clones ND
P20-CK-ZV 6/9 clones ND 7/7 clones ND
In MDCK-ST6 cells with oseltamivir P16-ST6-OV ND 0/8 clones ND 0/8 clones
P17-ST6-OV ND 0/8 clones ND 3/7 clones
P18-ST6-OV ND 5/7 clones ND 8/8 clones
P20-ST6-OV ND 5/8 clones ND 5/7 clones
HA, haemagglutinin; MDCK, Madin-Darby canine kidney; ND, not detected; NT, not tested.
aAmino acid numbering of NA and HA was based on N2 NA [16] and H3 HA [15] of inﬂuenza A virus, respectively.
bPassage number.
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lates with the NA Asp198 ﬁ Asn substitution (237.3 and
48.9 nM for oseltamivir and zanamivir, respectively) and NA
Ile222 ﬁ Thr substitution (479.9 and 23.3 nM for oseltamivir
and zanamivir, respectively) were comparable to those of the
corresponding in vitro isolates in this study (Table 2). These
results suggest that inﬂuenza B viruses isolated from patients
who were not treated with NA inhibitors must have been
selected in patients who were treated with an NA inhibitor
and then transmitted to others.
In addition to the NA substitutions, HA2 Arg65 ﬁ Gly
and HA1 Ile307 ﬁ Thr substitutions were detected in
viruses passaged with NA inhibitors (Table 1). HA with
decreased afﬁnity for receptor may partly contribute to the
reduced NA inhibitor sensitivity of viruses [14]. In fact, the
amino acid at position 65 in HA2 maps close to the second
ligand-binding site [14], whose signiﬁcance for HA receptor
binding is as yet unclear. Although the amino acid at posi-
tion 307 in HA1 is distant from the primary receptor-binding
site [14,15], the HA1 Ile307 ﬁ Thr substitution may also
play a role in the emergence of NA inhibitor-resistant
viruses.
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